All News

EULAR24,Roundup

EULAR 2024 Rheumatology Roundup (6.21.2024)

d Jack Cush, MD

Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna

Read Article
Update on Sjogren's disease trials With better endpoint and patient selection strategy over the last 4 years, many new therapies have met their endpoints/shown promising signal in the Phase 2 RCTs in Sjogren's disease. https://t.co/qMxEX73BsM https://t.co/CQWaAIO4IK

Links:

Dr. John Cush RheumNow ( View Tweet)
New Treatments for Systemic Sclerosis aHSCT for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed. https://t.co/xUI0plrk42 https://t.co/DqGUhU6D1Z

Links:

Dr. John Cush RheumNow ( View Tweet)
Camels and psoriatic arthritis - a new treatment link https://t.co/0SQt3UPmKu https://t.co/zvwH9iYtxX

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 – Day 4 Report The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations. Below is a synopsis of the half-day's action. https://t.co/1lQcu1beOm https://t.co/QHMcFzaG48

Links:

Dr. John Cush RheumNow ( View Tweet)
We've Got to Talk about CAR T cells Dr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria. https://t.co/mrr5MWxeJz https://t.co/0FMLaAxaWV

Links:

Dr. John Cush RheumNow ( View Tweet)
Select your GCA Therapy Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria. https://t.co/TPBeU7KaEq https://t.co/09uEzM3Kkd

Links:

Dr. John Cush RheumNow ( View Tweet)
Predicting Palindromic Prognosis Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria. https://t.co/Nc0XymI24l https://t.co/69qdLh63ct

Links:

Dr. John Cush RheumNow ( View Tweet)
Giant Cell Arteritis and Polymyalgia Rheumatica Update Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria. https://t.co/0V9Sle0GMU https://t.co/ixeT8L562C

Links:

Dr. John Cush RheumNow ( View Tweet)
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria. https://t.co/mv9DeZ9cez https://t.co/1OpT3MomO8

Links:

Dr. John Cush RheumNow ( View Tweet)
Update on low-dose glucocorticoids in SLE GC have been the mainstay of treatment in SLE for nearly 75 yrs. GC induce anti-inflammatory effects, quickly relieve symptoms, and reduce mortality in life-threatening flares through various actions. https://t.co/uEtWftvwEz https://t.co/nJlpELMj5W

Links:

Dr. John Cush RheumNow ( View Tweet)
Achieving drug-free remission in axSpA In early axSpA, over 60% achieved sustained inactive disease. Male, non-smokers, low BASDAI scores had higher remission rates. Drug-free remission remains challenging. https://t.co/Yv8a8C1hc9 https://t.co/JaYvfGry4P

Links:

Dr. John Cush RheumNow ( View Tweet)
POS0509 looks at time to diagnosis and #comorbidity burden in #axSpa Retrospective study in French THIN database Diagnostic delay remains common Increased number of MSK & non-MSK manifestations & #comorbidities over time vs 1st presentation of back pain #EULAR2024 @DrMiniDey https://t.co/egwDL1XjSw
Dr. John Cush RheumNow ( View Tweet)
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @Yuz6Yusof https://t.co/eSqOkBGBK2
Dr. John Cush RheumNow ( View Tweet)
Proportion of ILD patients on IS drugs has massively increased over time! Also good to see practices are changing & MTX is slowly creeping in Anna Maria Hoffmann-Vold, ILD management session #EULAR2024 @AurelieRheumo https://t.co/npa8O7g7l8
Dr. John Cush RheumNow ( View Tweet)
PMR has distinct patterns on MRI shoulder, possibly helping Dx. #EULAR2024 OP0248 @drdavidliew also @bmj_rmdopen https://t.co/0J3xUmb9yt where they say: "Similar to our prior findings... the target of inflammation in PMR is the outer covering of a tendon, the peritendineum" https://t.co/AzWkg3z2vR

Links:

Dr. John Cush RheumNow ( View Tweet)
How good are we at picking up depression in RA patients? In this Polish registry: - 1.8% had depression diagnosis - 21% had low mood on HAQ & depression has real correlates with disease activity. Plenty to think about with truly holistic RA care! #EULAR2024 POS1045 @drdavidliew https://t.co/ArfqHCKxhz
Dr. John Cush RheumNow ( View Tweet)
Choices in GCA https://t.co/e994wGiUwb https://t.co/psr9NV0OA6

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult-to-treat RA: are we any closer to predicting who is at risk? 4 years ago EULAR published its definition of D2T RA. This marked a formal recognition of patients who, despite the advances in pharmacological therapy for RA, remain symptomatic. https://t.co/kQJeUiRNtY https://t.co/xJEVihBMfm

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 – Day 3 Report We are sharing a few of our favorite abstracts and presentations from today, day 3 in Vienna. https://t.co/XgceAQFVQC https://t.co/80jrjv6Awn

Links:

Dr. John Cush RheumNow ( View Tweet)
×